Higher sales of key new medicines and cost cuts helped lift drugmaker Bristol-Myers Squibb Co.'s first-quarter profit by nearly 27 percent. The maker of melanoma drug Yervoy and schizophrenia treatment Abilify trounced Wall Street's profit forecast, beating expectations by 21 cents per share.Read more on NewsOK.com